Literature DB >> 2749583

Impaired energy metabolism in platelets from patients with Wiskott-Aldrich syndrome.

A J Verhoeven1, I E van Oostrum, H van Haarlem, J W Akkerman.   

Abstract

The platelet function defect seen in patients with Wiskott-Aldrich syndrome (WAS) has been ascribed to abnormal mitochondrial energy generation. The present study reveals a reduced energy content and low adenylate energy charge in platelets from two WAS-patients. Energy consumption in the resting platelets is slightly beyond the normal range, especially when ATP-resynthesis is primarily glycolytic. When platelets are stimulated with thrombin, the increase in energy consumption is 40-60% lower than in controls, both when energy is produced in glycolysis as when the mitochondria supply most of the energy. Analysis of the electron transport chain reveals no abnormalities. In contrast, the balance between glycolytic and mitochondrial ATP resynthesis is disturbed with a lowered contribution of oxidative ATP production. No such abnormalities are found in two WAS-carriers with the exception of a slight impairment in energy consumption during stimulation with thrombin. Thus, the platelet malfunction in WAS may be caused by a defect in the regulation of energy generation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2749583

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

1.  No evidence for altered muscle mitochondrial function in Parkinson's disease.

Authors:  J J Anderson; D Bravi; R Ferrari; T L Davis; F Baronti; T N Chase; F Dagani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

2.  Wiskott Aldrich syndrome protein regulates non-selective autophagy and mitochondrial homeostasis in human myeloid cells.

Authors:  Elizabeth Rivers; Rajeev Rai; Jonas Lötscher; Michael Hollinshead; Gasper Markelj; James Thaventhiran; Austen Worth; Alessia Cavazza; Christoph Hess; Mona Bajaj-Elliott; Adrian J Thrasher
Journal:  Elife       Date:  2020-11-02       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.